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cizumab according to two definitions of refrac-
toriness.2,3 Regardless of the definition, a lower 
percentage of patients in the caplacizumab group 
than in the placebo group had disease that was 
refractory to treatment, which suggests that 
 caplacizumab might prevent refractory TTP and 
its associated worse outcomes.1
To clarify, Table 3 of our article reports the 
cumulative number of patients with at least one 
adverse event that was considered to be related 
or possibly related to the investigational medici-
nal product, whereas the text separately reports 
the number of patients with at least one adverse 
event that was considered to be either related or 
possibly related to treatment. We confirm that 
the data regarding patients with relapse during 
the 12-month follow-up include those with re-
lapse during the 1-month follow-up: 11 patients 
in the caplacizumab group, as compared with 3 in 
the placebo group, had a relapse during the en-
tire follow-up period. Overall, 13 patients in each 
treatment group had at least one recurrence of 
TTP (exacerbation or relapse).
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Convalescent Plasma for Ebola Virus Disease
To the Editor: In their study, van Griensven et al. 
(Jan. 7 issue)1 found no significant survival bene-
fit of using convalescent plasma with unknown 
levels of neutralizing antibodies in patients with 
Ebola virus disease (EVD). Survivors of EVD donat-
ed plasma anywhere from 2 months to 6 months 
or more after they had recovered. Substantial 
immune activation and robust B-cell and T-cell 
responses have been observed in patients with 
acute EVD and in some patients during convales-
cence,2 although humoral response has not been 
thoroughly studied in EVD. We have found that 
in convalescent patients, specific neutralizing ac-
tivity against Ebola virus glycoprotein (EBOV-GP) 
increases over time (≥9 months after infection), 
which suggests that affinity maturation of anti-
bodies takes place long after clinical recovery.3 
The time that has elapsed after recovery from 
EVD may be a proxy for the level of activity of 
EBOV-GP–specific neutralizing antibodies. Given 
these data, we would be interested in whether 
patients who received plasma that had been do-
nated 6 months or more after recovery from EVD 
had a survival advantage over controls and over 
patients who had received plasma from survivors 
at earlier time points.
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Definition of Refractoriness
Caplacizumab 
(N = 35)
Placebo 
(N = 37)
number (percent)
No platelet response after 7 days, despite 
daily plasma-exchange therapy†
2 (6) 8 (22)‡
Absence of platelet-count doubling after 
4 days of standard treatment, with 
lactate dehydrogenase level >ULN§
0 4 (11)
*  ULN denotes upper limit of the normal range.
†  Definition is from Sayani and Abrams.2
‡  Two patients in the placebo group who discontinued the study prematurely 
(<7 days) without reaching the platelet-count criterion (i.e., platelet count, 
<150×109 per liter) were counted as having disease that was refractory to 
treatment.
§  Definition is from Soucemarianadin et al.3
Table 1. Post Hoc Analysis of Refractoriness to Treatment in the Safety 
Population of the TITAN Study.*
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To the Editor: Although the study by van Griens-
ven et al. suggests that the use of convalescent 
plasma in patients with EVD may have a small 
survival advantage only in particular populations, 
we identified several methodologic factors that 
could have increased the effectiveness of this 
treatment. First, the investigators did not include 
a characterization of neutralizing antibodies in 
the transfused products after viral inactivation 
and liquid storage for 40 days. Second, the stor-
age of plasma at 2 to 8 C° for 40 days before freez-
ing goes against international practices, which 
recommend freezing within 24 hours to preserve 
protein function from proteolysis or aggrega-
tion.1 This increases the risk of transfusing 
plasma that does not contain enough neutral-
izing antibodies. Third, the investigators pro-
vided limited data on antibody cross-reactivity 
against Ebola virus strains during antibody-based 
therapies,2 which further complicates interpreta-
tion of the data. Moreover, the decision not to 
screen Ebola survivors for transfusion-transmis-
sible infections before blood donation contravenes 
the guidelines of the World Health Organization.3 
We encourage the investigators to document les-
sons learned on safe plasma administration dur-
ing epidemics in countries with poorly developed 
infrastructure, since the use of convalescent plas-
ma may remain the first-line treatment during 
future Ebola outbreaks in developing countries.
Thierry Burnouf, Ph.D.
Taipei Medical University 
Taipei, Taiwan 
thburnouf@ gmail . com
Brian Conton
Physiofitness and Rehabilitation Center 
Freetown, Sierra Leone
John M. Dye, Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases 
Fort Detrick, MD
for the GET Consortium
The views expressed are those of the authors and do not nec-
essarily represent the official position of the U.S. Army.
No potential conflict of interest relevant to this letter was re-
ported.
1. World Health Organization. Use of convalescent whole 
blood or plasma collected from patients recovered from Ebola 
virus disease for transfusion, as an empirical treatment during 
outbreaks: interim guidance for national health authorities and 
blood transfusion services. 2014 (http://www .who .int/ csr/ resources/ 
publications/ ebola/ convalescent-treatment/ en/ ).
2. WHO guidelines on good manufacturing practices for blood 
establishments. WHO Technical Report Series 2011; Annex 4: 148-
214.
3. Casadevall A, Pirofski LA. The Ebola epidemic crystallizes 
the potential of passive antibody therapy for infectious diseases. 
PLoS Pathog 2015; 11(4): e1004717.
DOI: 10.1056/NEJMc1602284
To the Editor: We commend the effort of the 
Ebola-Tx trial team in investigating, under chal-
lenging circumstances, the use of convalescent 
plasma as a potential therapeutic option for EVD. 
However, in order to draw definitive conclusions, 
the investigators would have needed to evaluate 
the differences in clinical management in the two 
study groups. Although the efficacy of supportive 
care has not been evaluated in a clinical trial, multi-
ple groups with clinical expertise during EVD out-
breaks have agreed by consensus that such care is 
integral to decreasing EVD mortality.1,2 The authors 
acknowledge that patients in the convalescent-
plasma group may have received more intravenous 
fluids than patients in the control group owing to 
the previous placement of an intravenous catheter. 
However, the logistic-regression model for the study 
includes only the patient’s age and threshold-cycle 
value and omits variables that might have account-
ed for key between-group differences in clinical 
management. Such differences include fluid re-
suscitation and point-of-care electrolyte testing. 
Although the conduct of studies such as the Ebola-
Tx trial can be challenging, spurious interpreta-
tion of the incremental survival benefit of an ad-
junctive therapy such as convalescent plasma may 
occur when investigators do not account for the 
quality of clinical management across study groups.
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The authors reply: Arribas et al. suggest using 
the interval after recovery from EVD as a proxy 
for the level of neutralizing antibodies in the con-
valescent plasma. We had previously examined 
this variable and found no clear association with 
survival. In particular, patients who received 
plasma donated 6 or more months after cure did 
not have a survival advantage over other patients 
in the convalescent-plasma group (fatality rate, 
45% and 27%, respectively). Further study is need-
ed to determine whether there is an association 
between the level of neutralizing antibodies in 
the convalescent plasma and patient outcomes.
We agree with Burnouf et al. on the value of 
reporting on the feasibility of the collection and 
administration of convalescent plasma during an 
Ebola outbreak. We also agree that our finding 
that the use of convalescent plasma did not pro-
vide a significant benefit with respect to mortal-
ity demands further preclinical and clinical re-
search. As to donor prescreening, we had planned 
to screen patients for transfusion-transmissible 
infections before proceeding to apheresis. How-
ever, the local association of Ebola survivors, 
which was very closely involved in our project, 
insisted that survivors should be given the op-
tion of undergoing testing for infections and 
apheresis in a single step as well as the option 
of not being told the test results. All six ethics 
committees that reviewed the protocol, includ-
ing the WHO committee, thoroughly discussed 
this aspect of the study and agreed to the provi-
sion. Conditions for plasma storage were among 
those suggested in the relevant WHO guidance 
document.1 Freezing within 24 hours has been 
associated with the most effective recovery of 
labile coagulation factors and much less so with 
the maintenance of stable plasma proteins such 
as antibodies. Antibodies against the Ebola virus 
make up the presumably active component of 
convalescent plasma.2,3 With respect to testing of 
donor plasma for the presence of neutralizing 
antibodies before administration, the WHO guid-
ance document acknowledges that such testing 
may be impossible,1 since it requires the use of 
biosafety level 4 laboratories. Samples of conva-
lescent plasma have been shipped to France for 
analysis, including the measurement of antibody 
levels in Ebola patients before and after transfu-
sion of convalescent plasma.
We concur with Fletcher et al. with respect to 
the challenges in obtaining detailed information 
on the level of supportive care from Ebola treat-
ment centers that provide routine clinical care. 
This information was not reliably collected for 
the historical control group, which precluded ad-
justment in the analysis. We have acknowledged 
this lack of data as a study limitation.
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